M&A Deal Summary

Kedrion Acquires Prometic Bioproduction

On October 15, 2021, Kedrion acquired life science company Prometic Bioproduction from Liminal BioSciences

Acquisition Highlights
  • This is Kedrion’s 1st transaction in the Life Science sector.
  • This is Kedrion’s 1st transaction in Canada.
  • This is Kedrion’s 1st transaction in Quebec.

M&A Deal Summary
Date 2021-10-15
Target Prometic Bioproduction
Sector Life Science
Buyer(s) Kedrion
Sellers(s) Liminal BioSciences
Deal Type Divestiture

Target

Prometic Bioproduction

Laval, Quebec, Canada
Prometic Bioproduction has developed the first-ever FDA-approved treatment for Congenital Plasminogen Deficiency. The new drug, called Ryplazim has been approved for the treatment of all the clinical manifestations of Plasminogen Deficiency, which can lead to blindness, respiratory failure, and other severe complications.

Search 201,292 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Kedrion

Lucca, Italy
Category Company
Founded 2001
Sector Medical Products
Employees1,000
DESCRIPTION

Kedrion is engaged in development, manufacture, and distribution of a broad range of protein products derived from human plasma. Kedrion was founded in 2001 and is based in Lucca, Italy.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Divestiture) 1 of 1
State (Quebec) 1 of 1
Country (Canada) 1 of 1
Year (2021) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2021-04-07 Kedrion - U.S. Plasma Donation Centers

Wilmington, Delaware, United States

Kedrion's U.S. Plasma Donation Centers provide plasma supply through organic and inorganic growth with immediate access to approximately 1.4 million liters per year and obtain approximately 240,000 liters per year.

Sell $55M

Seller(S) 1

SELLER

Liminal BioSciences

Laval, Quebec, Canada
Category Company
Founded 1994
Sector Life Science
Employees251
Revenue 1M CAD (2021)
DESCRIPTION

Liminal BioSciences is a biopharmaceutical company with globally recognized expertise in bioseparations, plasma-derived therapeutics, and small-molecule drug development. The Company offers its state-of-the-art technologies for large-scale purification of biologics, drug development, proteomics and the elimination of pathogens to a growing base of industry leaders and uses its own affinity technology that provides for highly efficient extraction and purification of therapeutic proteins from human plasma in order to develop best-in-class therapeutics. Liminal BioSciences was founded in 1994 and is based in Laval, Canada.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Divestiture) 1 of 1
State (Quebec) 1 of 1
Country (Canada) 1 of 1
Year (2021) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2016-08-24 Telesta Therapeutics

Saint-Laurent, Quebec, Canada

Telesta Therapeutics, Inc. is a clinical stage biotechnology company focused on the development, manufacturing, and commercialization of proprietary and innovative therapeutics for the global human health market. The Company’s anchor product is in Phase III clinical development to treat non-muscle-invasive bladder cancer.

Buy -
Mergr

Product

Company

Legal